RnRMarketResearch.com add Global Idiopathic Pulmonary Fibrosis Market 2016-2020 latest research report, the analysts forecast global idiopathic pulmonary fibrosis market to grow at a CAGR of 23.97% during the period 2016-2020.
The following companies are the key players in the global idiopathic pulmonary fibrosis market: Baxter International, Boehringer Ingelheim, F.Hoffmann-La Roche, and Prometheus Laboratories.
Other Prominent Vendors in the market are: Afferent Pharmaceuticals, Amgen, Biogen, Bristol-Myers Squibb, Cipla, FibroGen, Gilead Sciences, GlaxoSmithKline, GNI Group, Horizon Pharma, ImmuneWorks, MediciNova, MedImmune (subsidiary of AstraZeneca), Novartis, Pfizer, Promedior, ProMetic Life Sciences, Sanofi, Shionogi, and Zai Lab.
Inquire for Discount at @ http://www.rnrmarketresearch.com/contacts/discount?rname=542965
According to the idiopathic pulmonary fibrosis market report a possible growth driver is the unmet medical needs of many patients. Due to the unknown disease etiology, there is no specific cure for idiopathic pulmonary fibrosis. Therapies that target the exact cause of the disease cannot be developed owing to the idiopathic nature of the disease. Even the drugs marketed for the symptomatic treatment of the disease present different effects such as upper respiratory tract infections, liver problems, nausea and vomiting, diarrhea, headache, heartburn, weight loss, and high blood pressure. This results in decreased patient compliance, creating an unmet need in the market. Pharmaceutical companies and researchers are interested in developing a drug that provides a complete cure for the disease, with minimal side effects.
The global idiopathic pulmonary fibrosis market analyst said emerging market trend is the rise in patient assistance programs. Vendors in the market provide co-pay assistance to people who purchase the indicated medications for idiopathic pulmonary fibrosis. For instance, Roche has a co-pay assistance program to provide financial assistance to patients who purchase Esbriet. According to the Esbriet Co-pay Card Program, an eligible patient receives a 12-month prescription free of cost, attaining a maximum benefit of $24,000 during this period. The company also provides Esbriet Access Solutions that provide co-pay cards, assistance in getting drugs, and provide healthcare coverage to patients.
Order a copy of Global Idiopathic Pulmonary Fibrosis Market 2016-2020 report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=542965
Global Idiopathic Pulmonary Fibrosis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
The report covers the present scenario and the growth prospects of the global idiopathic pulmonary fibrosis market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of idiopathic pulmonary fibrosis.
Idiopathic pulmonary fibrosis belongs to a group of lung diseases known as interstitial lung diseases. It affects people in the age group 50-70 years. Diagnosis is effected by the exclusion of other interstitial lung diseases. High-resolution computed tomography (CT) is often employed to confirm the presence of the disease. There is no permanent cure for this disease; therefore, treatment involves relieving underlying symptoms. Nintedanib and pirfenidone are the two approved drugs for the treatment of idiopathic pulmonary fibrosis. Corticosteroids and immunosuppressive drugs are also used for the treatment.
Further, the report states that one challenge that could market growth is the lack of proper diagnosis of this condition.
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Common symptoms of idiopathic pulmonary fibrosis
Exhibit 03: Other signs and symptoms of idiopathic pulmonary fibrosis
Exhibit 04: Treatment options for idiopathic pulmonary fibrosis
Exhibit 05: Drugs used in the treatment of idiopathic pulmonary fibrosis
Exhibit 06: Global idiopathic pulmonary fibrosis market: Pipeline portfolio
Exhibit 07: Global idiopathic pulmonary fibrosis market 2015-2020 ($ billions)
Exhibit 08: Five forces analysis
Exhibit 09: Segmentation of global idiopathic pulmonary fibrosis drugs market by ROA
Exhibit 10: Global idiopathic pulmonary fibrosis drugs market segment by drug class
Exhibit 11: Global idiopathic pulmonary fibrosis market segmentation by geography 2015
Exhibit 12: Idiopathic pulmonary fibrosis market revenue by geography 2015-2020 ($ millions)
Exhibit 13: Idiopathic pulmonary fibrosis market in Americas 2015-2020 ($ millions)
Exhibit 14: Idiopathic pulmonary fibrosis market in EMEA 2015-2020 ($ millions)
Exhibit 15: Idiopathic pulmonary fibrosis market in APAC 2015-2020 ($ millions)
Exhibit 16: Key drivers
Exhibit 17: Impact of drivers
Exhibit 18: Key challenges
Exhibit 19: Impact of drivers and challenges
Exhibit 20: Key trends
RnR Market Research
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Connect with Us:
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
RSS / Feeds: http://www.rnrmarketresearch.com/feed
P: + 1 888 391 5441